Patents Assigned to Intergalactic Therapeutics, Inc.
  • Synthetic DNA vectors and methods of use
    Patent number: 11766490
    Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: September 26, 2023
    Assignee: Intergalactic Therapeutics, Inc.
    Inventors: Bruce C. Schnepp, Philip R. Johnson
  • Synthetic DNA vectors and methods of use
    Patent number: 11684680
    Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: June 27, 2023
    Assignee: INTERGALACTIC THERAPEUTICS, INC.
    Inventors: Bruce C. Schnepp, Philip R. Johnson
  • Synthetic DNA vectors and methods of use
    Patent number: 11602569
    Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: March 14, 2023
    Assignee: Intergalactic Therapeutics, Inc.
    Inventors: Bruce C. Schnepp, Philip R. Johnson
  • Synthetic DNA vectors and methods of use
    Patent number: 11324839
    Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: May 10, 2022
    Assignee: Intergalactic Therapeutics, Inc. b
    Inventors: Bruce C. Schnepp, Philip R. Johnson